Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD

Add to favourite

2.0310

0.25%

0.0730

Low: 2.016

High: 2.076

Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 15:30

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0730

Long position overnight fee

-0.02529%

Short position overnight fee

0.003373%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

GBP

Margin

Stock exchange

United Kingdom of Great Britain and Northern Ireland

Commission on trade

*Information provided by Capital.com

PureTech Health PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	2.036
Open*	2.061
1-Year Change*	-5.07%
Day's Range*	2.016 - 2.076
52 wk Range	1.39-2.85
Average Volume (10 days)	689.99K
Average Volume (3 months)	9.28M
Market Cap	505.82M
P/E Ratio	-100.00K
Shares Outstanding	270.99M
Revenue	9.24M
EPS	-0.13
Dividend (Yield %)	N/A
Beta	1.16
Next Earnings Date	Apr 25, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	2.0310	0.0250	1.25%	2.0060	2.0810	2.0010
Apr 18, 2024	2.0360	-0.0200	-0.97%	2.0560	2.1060	2.0060
Apr 17, 2024	2.0510	-0.0050	-0.24%	2.0560	2.1060	2.0410
Apr 16, 2024	2.0560	-0.0400	-1.91%	2.0960	2.1110	2.0410
Apr 15, 2024	2.1310	0.0300	1.43%	2.1010	2.1510	2.0560
Apr 12, 2024	2.1360	-0.0195	-0.90%	2.1555	2.1710	2.1010
Apr 11, 2024	2.1510	0.0250	1.18%	2.1260	2.1855	2.1060
Apr 10, 2024	2.1560	0.0600	2.86%	2.0960	2.1755	2.0960
Apr 9, 2024	2.1110	-0.0350	-1.63%	2.1460	2.1810	2.1110
Apr 8, 2024	2.1360	0.0250	1.18%	2.1110	2.1760	2.0910
Apr 5, 2024	2.1710	0.0600	2.84%	2.1110	2.1760	2.0910
Apr 4, 2024	2.1555	0.0195	0.91%	2.1360	2.1760	2.1260
Apr 3, 2024	2.1410	0.0005	0.02%	2.1405	2.1760	2.1110
Apr 2, 2024	2.1460	-0.0745	-3.36%	2.2205	2.2355	2.1410
Mar 28, 2024	2.1855	-0.0150	-0.68%	2.2005	2.2555	2.1455
Mar 27, 2024	2.2405	0.0400	1.82%	2.2005	2.2455	2.1605
Mar 26, 2024	2.1755	-0.0650	-2.90%	2.2405	2.2955	2.1755
Mar 25, 2024	2.2355	0.1195	5.65%	2.1160	2.2855	2.1160
Mar 22, 2024	2.1560	-0.0045	-0.21%	2.1605	2.1660	2.0660
Mar 21, 2024	2.1510	-0.0245	-1.13%	2.1755	2.2055	2.1210

PURETECH HEALTH PLC ORD 1P Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 06:00	Country US	Event Full Year 2023 PureTech Health PLC Earnings Release Full Year 2023 PureTech Health PLC Earnings Release Forecast - Previous -
Wednesday, June 12, 2024
Time (UTC) 15:00	Country US	Event PureTech Health PLC Annual Shareholders Meeting PureTech Health PLC Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 27, 2024
Time (UTC) 12:30	Country US	Event Half Year 2024 PureTech Health PLC Earnings Release Half Year 2024 PureTech Health PLC Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	15.618	17.388	11.768	9.807	20.748
Revenue	15.618	17.388	11.768	9.807	20.748
Total Operating Expense	166.344	167.67	131.299	-521.847	114.221
Selling/General/Admin. Expenses, Total	60.991	57.199	49.44	59.358	47.365
Research & Development	152.433	110.471	81.859	85.848	77.402
Unusual Expense (Income)	-47.081	0	0	-667.053	-10.546
Operating Income	-150.726	-150.282	-119.531	531.654	-93.473
Interest Income (Expense), Net Non-Operating	-80.512	81.55	141.701	-18.634	21.253
Other, Net	138.455	9.779	-3.171	-34.464	-0.278
Net Income Before Taxes	-92.783	-58.953	18.969	478.474	-68.438
Net Income After Taxes	-37.064	-62.709	4.568	366.065	-70.659
Minority Interest	-13.29	2.151	1.417	55.079	27.005
Net Income Before Extra. Items	-50.354	-60.558	5.985	421.144	-43.654
Net Income	-50.354	-60.558	5.985	421.144	-43.654
Income Available to Common Excl. Extra. Items	-50.354	-60.558	5.985	421.144	-43.654
Income Available to Common Incl. Extra. Items	-50.354	-60.558	5.985	421.144	-43.654
Diluted Net Income	-50.354	-60.558	5.985	421.144	-43.654
Diluted Weighted Average Shares	287.797	286.591	292.856	283.426	273.848
Diluted EPS Excluding Extraordinary Items	-0.17496	-0.2113	0.02044	1.4859	-0.15941
Diluted Normalized EPS	-0.2813	-0.2113	0.0205	-0.0437	-0.19408
Gain (Loss) on Sale of Assets			-0.03	-0.082	4.06
Dilution Adjustment
Other Operating Expenses, Total	0.001

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total revenue	3.15	8.588	7.03	11.552	5.836
Revenue	3.15	8.588	7.03	11.552	5.836
Total Operating Expense	17.526	113.736	52.608	93.754	73.916
Selling/General/Admin. Expenses, Total	26.166	37.347	23.644	31.613	25.586
Research & Development	53.146	67.854	84.579	62.141	48.33
Unusual Expense (Income)	-61.787	8.533	-55.614	0
Operating Income	-14.376	-105.148	-45.578	-82.202	-68.08
Interest Income (Expense), Net Non-Operating	2.875	-7.841	-72.671	96.406	-14.856
Gain (Loss) on Sale of Assets
Other, Net	-2.243	76.163	62.292	21.774	-11.995
Net Income Before Taxes	-13.744	-36.826	-55.957	35.978	-94.931
Net Income After Taxes	-25.551	-13.592	-23.472	14.844	-77.553
Minority Interest	0.546	-8.418	-4.872	-0.007	2.158
Net Income Before Extra. Items	-25.005	-22.01	-28.344	14.837	-75.395
Net Income	-25.005	-22.01	-28.344	14.837	-75.395
Income Available to Common Excl. Extra. Items	-25.004	-22.01	-28.344	14.837	-75.395
Income Available to Common Incl. Extra. Items	-25.004	-22.01	-28.344	14.837	-75.395
Diluted Net Income	-25.004	-22.01	-28.344	14.837	-75.395
Diluted Weighted Average Shares	278.254	287.839	287.754	287.171	286.011
Diluted EPS Excluding Extraordinary Items	-0.08986	-0.07647	-0.0985	0.05167	-0.26361
Diluted Normalized EPS	-0.23419	-0.0572	-0.22413	0.05167	-0.26361
Dividends per Share - Common Stock Primary Issue	0		0		0
Other Operating Expenses, Total	0.001	0.002	-0.001
Total Adjustments to Net Income	0.001

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	386.192	501.809	414.348	168.845	259.786
Cash and Short Term Investments	352.219	467.832	406.005	164.572	253.078
Cash & Equivalents	149.866	465.708	403.881	132.36	117.051
Short Term Investments	202.353	2.124	2.124	32.212	136.027
Total Receivables, Net	22.357	23.223	2.939	2.327	1.328
Accounts Receivable - Trade, Net	11.867	3.174	2.558	1.977	1.328
Prepaid Expenses	11.617	10.755	5.405	1.946	5.38
Total Assets	702.647	946.006	989.994	941.178	441.763
Property/Plant/Equipment, Total - Net	37.238	43.937	42.875	43.838	8.323
Property/Plant/Equipment, Total - Gross	57.318	58.282	53.395	51.03	14.388
Accumulated Depreciation, Total	-20.08	-14.345	-10.521	-7.192	-6.065
Intangibles, Net	0.831	0.987	0.899	0.625	3.08
Long Term Investments	261.039	397.179	530.161	725.547	169.755
Other Long Term Assets, Total	0.011	0.809	0.011	0.241	0.819
Total Current Liabilities	96.885	226.135	180.924	139.201	265.764
Accounts Payable	26.504	11.346	8.871	11.098	4.644
Accrued Expenses	26.323	22.012	9.09	8.744	11.231
Notes Payable/Short Term Debt	2.345	3.916	26.455	1.455	12.01
Other Current Liabilities, Total	31.586	184.055	133.248	114.975	237.879
Total Liabilities	160.427	352.491	320.246	273.14	166.256
Total Long Term Debt	34.399	43.301	46.906	34.914	0
Minority Interest	5.369	-9.368	-16.209	-17.64	-108.535
Other Liabilities, Total	4.129	2.658	-0.001	1.22	2.599
Total Equity	542.22	593.515	669.748	668.038	275.507
Common Stock	5.455	5.444	5.417	5.408	5.375
Additional Paid-In Capital	289.624	289.303	288.978	287.962	278.385
Retained Earnings (Accumulated Deficit)	273.544	298.3	374.885	374.668	-8.263
Other Equity, Total	0.089	0.468	0.468	0	0.01
Total Liabilities & Shareholders’ Equity	702.647	946.006	989.994	941.178	441.763
Total Common Shares Outstanding	289.162	287.797	285.885	285.371	282.494
Deferred Income Tax	19.645	89.765	108.626	115.445	6.428
Note Receivable - Long Term	17.336	1.285	1.7	2.082
Current Port. of LT Debt/Capital Leases	10.128	4.807	3.261	2.929
Capital Lease Obligations	24.155	29.04	32.088	34.914
Other Current Assets, Total	-0.001	-0.001	-0.001
Payable/Accrued	-0.001	-0.001	-0.001
Long Term Debt	10.244	14.261	14.818
Treasury Stock - Common	-26.492

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total Current Assets	360.099	386.192	381.811	501.809	451.057
Cash and Short Term Investments	352.139	352.219	368.034	467.832	441.89
Cash & Equivalents	350.515	149.866	365.91	465.708	439.766
Short Term Investments	1.624	202.353	2.124	2.124	2.124
Total Receivables, Net	2.301	22.357	9.315	23.223	3.836
Accounts Receivable - Trade, Net	2.102	11.867	4.369	3.174	3.438
Prepaid Expenses	5.659	11.617	4.463	10.755	5.331
Total Assets	693.552	702.647	823.153	946.006	896.883
Property/Plant/Equipment, Total - Net	21.497	37.238	41.399	43.937	41.953
Property/Plant/Equipment, Total - Gross		57.318	58.43	58.282	54.62
Accumulated Depreciation, Total		-20.08	-17.03	-14.345	-12.667
Intangibles, Net	0.931	0.831	0.968	0.987	0.898
Long Term Investments	285.204	261.039	397.899	397.179	401.468
Note Receivable - Long Term	24.865	17.336	1.065	1.285	1.497
Other Long Term Assets, Total	0.956	0.011	0.011	0.809	0.01
Total Current Liabilities	49.265	96.885	150.254	226.135	213.948
Payable/Accrued	-0.001	-0.001	-0.001	35.817	39.85
Notes Payable/Short Term Debt	0	2.345	1.455	3.916	28.69
Current Port. of LT Debt/Capital Leases	5.58	10.128	8.064	4.807	3.46
Other Current Liabilities, Total	12.439	31.586	109.816	181.595	141.948
Total Liabilities	179.883	160.427	241.396	352.491	328.886
Total Long Term Debt	19.996	34.399	38.578	43.301	45.437
Capital Lease Obligations	19.996	24.155	26.697	29.04	30.463
Deferred Income Tax	9.084	19.645	57.277	89.765	74.468
Minority Interest	-4.778	5.369	-5.733	-9.368	-6.625
Other Liabilities, Total	106.316	4.129	1.02	2.658	1.658
Total Equity	513.669	542.22	581.757	593.515	567.997
Common Stock	5.461	5.455	5.446	5.444	5.419
Additional Paid-In Capital	290.262	289.624	289.301	289.303	289.013
Retained Earnings (Accumulated Deficit)	250.869	273.544	291.345	298.3	273.097
Other Equity, Total	0.182	0.089	-0.068	0.468	0.468
Total Liabilities & Shareholders’ Equity	693.552	702.647	823.153	946.006	896.883
Total Common Shares Outstanding	289.162	289.162	287.797	287.797	286.531
Other Current Assets, Total		-0.001	-0.001	-0.001
Long Term Debt	0	10.244	11.881	14.261	14.974
Accounts Payable	8.725	26.504	15.094
Accrued Expenses	22.522	26.323	15.826
Treasury Stock - Common	-33.105	-26.492	-4.267

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-37.065	-62.709	4.568	366.065	-70.659
Cash From Operating Activities	-178.793	-158.274	-131.827	-98.156	-72.796
Cash From Operating Activities	8.893	7.287	6.645	6.665	2.778
Non-Cash Items	-145.939	-72.779	-112.281	-599.144	-16.602
Changes in Working Capital	-4.682	-30.073	-30.759	16.181	9.964
Cash From Investing Activities	-107.223	197.375	364.478	63.659	-39.645
Capital Expenditures	-2.176	-5.661	-5.424	-12.538	-4.49
Other Investing Cash Flow Items, Total	-105.047	203.036	369.902	76.197	-35.155
Cash From Financing Activities	-29.826	22.726	38.869	49.91	156.887
Financing Cash Flow Items	-0.041	-14.142	-12.889	-1.28	-1.07
Issuance (Retirement) of Stock, Net	-26.153	38.028	14.878	51.552	151.995
Issuance (Retirement) of Debt, Net	-3.632	-1.16	36.88	-0.25	5.962
Foreign Exchange Effects		0	0	-0.104	-0.044
Net Change in Cash	-315.842	61.827	271.52	15.309	44.402
Deferred Taxes				112.077	1.723
Cash Interest Paid	3.366	3.382	2.651	2.495
Total Cash Dividends Paid		0	0	-0.112
Cash Taxes Paid	20.696	27.766	20.737

	Dec 2022	Jun 2022	Dec 2021	Jun 2021	Dec 2020
Net income/Starting Line	-37.065	-23.472	-62.709	-77.553	4.568
Cash From Operating Activities	-178.793	-87.249	-158.274	-65.366	-131.827
Cash From Operating Activities	8.893	4.294	7.287	3.648	6.645
Deferred Taxes
Non-Cash Items	-145.939	-74.093	-72.779	15.636	-112.281
Cash Interest Paid	3.366	1.633	3.382	1.705	2.651
Changes in Working Capital	-4.682	6.022	-30.073	-7.097	-30.759
Cash From Investing Activities	-107.223	-6.884	197.375	114.964	364.478
Capital Expenditures	-2.176	-1.647	-5.661	-2.724	-5.424
Other Investing Cash Flow Items, Total	-105.047	-5.237	203.036	117.688	369.902
Cash From Financing Activities	-29.826	-5.665	22.726	-13.713	38.869
Financing Cash Flow Items	-0.041	-0.004	-14.142	-13.746	-12.889
Total Cash Dividends Paid			0		0
Issuance (Retirement) of Stock, Net	-26.153	-4.26	38.028	0.043	14.878
Issuance (Retirement) of Debt, Net	-3.632	-1.401	-1.16	-0.01	36.88
Foreign Exchange Effects			0	0	0
Net Change in Cash	-315.842	-99.798	61.827	35.885	271.52
Cash Taxes Paid	20.696	0	27.766	3.364	20.737

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Puretech Health plc Company profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Industry:

Biotechnology & Medical Research (NEC)

6 Tide Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024